Expression and Clinical Significance of PIEZO2 in Gastric Cancer.

Abstract

The aim of this research was to investigate the expression of PIEZO2 and its potential clinical significance in gastric cancer (GC). In this study, we detected the protein expression levels of PIEZO2 in GC tissues and adjacent normal tissues by immunohistochemistry (IHC) and analysed the relationship between the protein expression levels of PIEZO2 and clinicopathological parameters of GC patients. Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier Plotter were used to verify the diagnostic and prognostic values of PIEZO2. Proteins interacting with PIEZO2 were predicted using the SRING database. Our results showed that the protein expression levels of PIEZO2 in GC tissues were lower than those in adjacent normal tissues (all P < 0.05), and the protein expression level of PIEZO2 was correlated with lymph node metastasis and TNM stage of GC patients (all P < 0.05). Aberrant overexpression of PIEZO2 was associated with poor prognosis of GC patients. Proteins such as VR1, TRPV1, LHFPL5, STOM, TRPA1 and STOML3 had obvious interactions with PIEZO2 (P = 0.00213). In summary, our current study identified PIEZO2 as a promising target for early diagnosis and as a potential prognostic biomarker in GC patients.